Patents by Inventor David Nigel Armstrong

David Nigel Armstrong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10881640
    Abstract: A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treatment. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: January 5, 2021
    Assignee: S.L.A. PHARMA AG
    Inventors: David Nigel Armstrong, Justin Slagel
  • Patent number: 10709689
    Abstract: A topical composition comprises at least 5 wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: July 14, 2020
    Assignee: SLA PHARMA AG
    Inventor: David Nigel Armstrong
  • Patent number: 10653671
    Abstract: A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treatment. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 19, 2020
    Assignee: S.L.A. PHARMA, AG
    Inventors: David Nigel Armstrong, Justin Slagel
  • Publication number: 20190175558
    Abstract: A topical composition comprising about 5 wt % to about 25 wt % of metronidazole or a pharmacologically acceptable salt thereof in a carrier. The composition may be used in the treatment of tissue damage from surgery, infections and other damaging diseases. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 13, 2019
    Inventors: David Nigel ARMSTRONG, Justin SLAGEL
  • Patent number: 9655883
    Abstract: A topical composition comprises at least 5-wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, and anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: May 23, 2017
    Assignee: SLA PHARMA AG
    Inventor: David Nigel Armstrong
  • Publication number: 20160346253
    Abstract: A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treatment. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided.
    Type: Application
    Filed: August 11, 2016
    Publication date: December 1, 2016
    Inventors: DAVID NIGEL ARMSTRONG, JUSTIN SLAGEL
  • Publication number: 20140271921
    Abstract: A topical composition comprises at least 5 wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.
    Type: Application
    Filed: May 28, 2014
    Publication date: September 18, 2014
    Applicant: SLA PHARMA AG
    Inventor: DAVID NIGEL ARMSTRONG
  • Publication number: 20140256661
    Abstract: The present invention relates to a pharmaceutical composition, in particular a composition formulated for enema administration, wherein the composition comprises metronidazole or a pharmacologically acceptable derivative thereof in an amount to effectively treat both acute and chronic pouchitis and/or proctitis.
    Type: Application
    Filed: July 12, 2012
    Publication date: September 11, 2014
    Inventor: David Nigel Armstrong
  • Publication number: 20100305178
    Abstract: A topical composition comprises at least 5-wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, and anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.
    Type: Application
    Filed: July 12, 2010
    Publication date: December 2, 2010
    Applicant: Armstrong Medical Inc.
    Inventor: David Nigel Armstrong